German firm Isotope Technologies Garching (ITG) and nuclear reactor operator Bruce Power have signed a memorandum of understanding for the joint production of the radioisotope lutetium-177 (Lu-177).
ITG has developed a method for creating a unique form of Lu-177, noncarrier-added (NCA) Lu-177, with a relatively high specific activity, according to the companies. The firms have agreed to manufacture NCA Lu-177 at Bruce Power's commercially operating reactors using ITG's proprietary production technique.
ITG is a subsidiary of ITM Isotopen Technologien München, a group of radiopharmaceutical companies that will manage the development, processing, and distribution of NCA Lu-177.
